Bollard Group buys $24,639,038 stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Bollard Group scooped up 1,066 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 20, 2016. The investment management firm now holds a total of 301,986 shares of Eli Lilly and Co which is valued at $24,639,038.Eli Lilly and Co makes up approximately 1.66% of Bollard Group’s portfolio.

Other Hedge Funds, Including , Catawba Capital Management Va boosted its stake in LLY in the latest quarter, The investment management firm added 250 additional shares and now holds a total of 7,898 shares of Eli Lilly and Co which is valued at $634,051. Eli Lilly and Co makes up approx 0.15% of Catawba Capital Management Va’s portfolio.Livforsakringsbolaget Skandia Omsesidigt boosted its stake in LLY in the latest quarter, The investment management firm added 7,800 additional shares and now holds a total of 119,317 shares of Eli Lilly and Co which is valued at $9,539,394. Eli Lilly and Co makes up approx 0.41% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio.West Oak Capital reduced its stake in LLY by selling 145 shares or 1.29% in the most recent quarter. The Hedge Fund company now holds 11,120 shares of LLY which is valued at $885,819. Eli Lilly and Co makes up approx 0.63% of West Oak Capital’s portfolio.

Eli Lilly and Co opened for trading at $80.27 and hit $80.52 on the upside on Wednesday, eventually ending the session at $80.28, with a gain of 0.39% or 0.31 points. The heightened volatility saw the trading volume jump to 28,11,087 shares. Company has a market cap of $88,616 M.

On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.

Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.